Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
Mem. Inst. Oswaldo Cruz
; 109(6): 828-833, 09/09/2014. tab, graf
Article
en En
| LILACS
| ID: lil-723996
Biblioteca responsable:
BR1.1
ABSTRACT
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
LILACS
Asunto principal:
Tripanocidas
/
Trypanosoma cruzi
/
Enfermedad de Chagas
/
Descubrimiento de Drogas
Tipo de estudio:
Guideline
Idioma:
En
Revista:
Mem. Inst. Oswaldo Cruz
Asunto de la revista:
MEDICINA TROPICAL
/
PARASITOLOGIA
Año:
2014
Tipo del documento:
Article
País de afiliación:
Brasil